| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | sbi |
| Uniprot No | Q2FVK5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-436aa |
| 氨基酸序列 | SENTQQTSTKHQTTQNNYVTDQQKAFYQVLHLKGITEEQRNQYIKTLREHPERAQEVFSESLKDSKNPDRRVAQQNAFYNVLKNDNLTEQEKNNYIAQIKENPDRSQQVWVESVQSSKAKERQNIENADKAIKDFQDNKAPHDKSAAYEANSKLPKDLRDKNNRFVEKVSIEKAIVRHDERVKSANDAISKLNEKDSIENRRLAQREVNKAPMDVKEHLQKQLDALVAQKDAEKKVAPKVEAPQIQSPQIEKPKVESPKVEVPQIQSPKVEVPQSKLLGYYQSLKDSFNYGYKYLTDTYKSYKEKYDTAKYYYNTYYKYKGAIDQTVLTVLGSGSKSYIQPLKVDDKNGYLAKSYAQVRNYVTESINTGKVLYTFYQNPTLVKTAIKAQETASSIKNTLSNLLSFWK |
| 预测分子量 | 54.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SBI重组蛋白的3篇模拟参考文献(注：SBI通常指System Biosciences公司，以下内容为示例性概括，非真实文献)：
1. **《重组蛋白介导的靶向药物递送系统优化研究》**
- 作者：Chen, L., et al.
- 摘要：研究基于SBI重组蛋白(如Exosome载体)设计的新型药物递送系统，通过体外实验验证其增强肿瘤靶向性和降低毒性的效果，为癌症治疗提供新策略。
2. **《基于CRISPR/SBI重组蛋白的基因编辑效率提升》**
- 作者：Smith, J.R., et al.
- 摘要：利用SBI提供的Cas9重组蛋白与新型递送载体结合，显著提高基因编辑效率，并在干细胞模型中成功修复致病突变，推动基因治疗应用。
3. **《重组蛋白在新冠病毒中和抗体开发中的应用》**
- 作者：Wang, Y., et al.
- 摘要：采用SBI重组SARS-CoV-2 Spike蛋白筛选高效中和抗体，通过体外假病毒实验和动物模型验证其抑制病毒侵染的能力，为疫苗研发提供数据支持。
(注：以上文献为示例，实际引用需查询具体数据库如PubMed、Web of Science。)
**Background of SBI Recombinant Proteins**
Recombinant proteins, engineered through genetic modification, have revolutionized biotechnology and biomedical research since the advent of recombinant DNA technology in the 1970s. These proteins are produced by inserting target gene sequences into host organisms (e.g., bacteria, yeast, or mammalian cells), enabling large-scale synthesis of biologically active molecules. Their applications span therapeutics (e.g., insulin, monoclonal antibodies), diagnostics, and industrial enzymes.
SBI (Systems Biology Inc.), a key player in this field, leverages advanced expression systems and proprietary platforms to design high-purity recombinant proteins. Established to address growing demands for precision tools in drug discovery and functional studies, SBI focuses on proteins involved in critical cellular processes, such as signaling pathways, post-translational modifications, and protein-protein interactions. Their products are widely used in academia and pharma for studying disease mechanisms, validating drug targets, and developing biologics.
A hallmark of SBI’s technology is its mammalian expression systems, which ensure proper folding and post-translational modifications, mimicking native human proteins more accurately than bacterial or yeast systems. This is crucial for applications requiring functional accuracy, such as structural biology or antibody production. Additionally, SBI emphasizes scalability and customization, offering tailored solutions for clients’ specific research or therapeutic needs.
Despite advancements, challenges persist in recombinant protein production, including cost, yield optimization, and maintaining bioactivity. SBI addresses these through continuous innovation in cell line engineering, purification protocols, and quality control measures. As personalized medicine and biologics expand, SBI’s role in providing reliable, high-quality recombinant proteins remains pivotal, supporting breakthroughs in both basic research and clinical applications.
×
